MASSDEVICE ON CALL — Researchers touted positive outcomes for the 1st study to compare a traditional insulin pump to a dual-hormone "artificial pancreas" in treating patients with diabetes.
The Canadian team reported that patients using the experimental technology showed improved glucose levels and lower risks of hypoglycemia, potentially advancing research into a commercially viable artificial pancreas.
"We found that the artificial pancreas improved glucose control by 15% and significantly reduced the risk of hypoglycemia as compared with conventional insulin pump therapy," primary study author and doctoral student Ahmad Haidar said in prepared remarks.
The artificial pancreas provides automated delivery of both insulin and glucagon as necessary based on readings from a continuous glucose monitor.
A study published last year reported that progress in artificial pancreas therapy could save Medicare nearly $1 billion over 25 years.
Mass. life sciences incubator touts surgical gel sales
The Massachusetts Life Sciences Center, a quasi-public agency and incubator for biotechnology startups, touted the commercial launch of a surgical gel technology developed with the help of funding from the center’s Accelerator Loan Program.
Sunshine rules still not ready, interest groups say
The Physician Payment Sunshine Act rules, which would require healthcare companies to disclose financial relationships with physicians, need more work before taking effect, interest groups such as the American Medical Assn. told Congress.
Healthcare IT firms garner $1.2B in funding in 2012
Healthcare information technology companies rounded up nearly $1.2 billion in venture capital funding through more than 160 deals in 2012, a 150% increase from the $480 million raised in 2011.